Introduction to Tofacinix 11 mg (Tofacitinib)
Tofacinix 11 mg, meticulously developed by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, represents a significant advancement in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Tofacitinib, the active ingredient in Tofacinix, offers a targeted approach, providing relief and improved outcomes for individuals suffering from these chronic conditions.
Description: Tofacinix 11 mg (Tofacitinib)
Tofacinix 11 mg contains Tofacitinib, a Janus kinase (JAK) inhibitor. This medication modulates the immune system by inhibiting the activity of specific enzymes involved in the inflammatory process.
Mechanism of Action
Tofacitinib works by targeting and inhibiting the Janus kinase enzymes (JAK1 and JAK3) involved in the signaling pathways that lead to inflammation and immune response. By blocking these pathways, Tofacinix 11 mg reduces inflammation and alleviates symptoms of RA and PsA.
Clinical Use
Tofacinix 11 mg is primarily prescribed for:
- Rheumatoid Arthritis (RA): For the treatment of moderate to severe RA in patients who have had an inadequate response to, or are intolerant of, methotrexate.
- Psoriatic Arthritis (PsA): For the treatment of active PsA in patients who have had an inadequate response to, or are intolerant of, disease-modifying antirheumatic drugs (DMARDs).
Dosage and Administration
Healthcare professionals determine the appropriate dosage of Tofacinix 11 mg based on the specific needs of the patient. The standard regimen involves taking one tablet (11 mg Tofacitinib) orally once daily. Dosage adjustments may be required based on patient response and tolerability.
Benefits of Tofacinix 11 mg (Tofacitinib)
- Targeted Therapy: Specifically inhibits JAK enzymes involved in the inflammatory process, offering a precise treatment approach.
- Symptom Relief: Effectively reduces symptoms of RA and PsA, including joint pain, swelling, and stiffness.
- Improved Quality of Life: Demonstrates significant efficacy in improving physical function and quality of life for patients with RA and PsA.
- Well-Tolerated: Generally well-tolerated with a manageable side effect profile, enhancing patient adherence to therapy.
Storage Conditions
Store Tofacinix 11 mg tablets at room temperature, between 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep out of reach of children.
Manufacturer: Beacon Pharmaceuticals Ltd
Beacon Pharmaceuticals Ltd, the esteemed manufacturer of Tofacinix 11 , is committed to producing high-quality medications. Their dedication to innovation and stringent quality control ensures that Tofacinix meets the highest standards of efficacy and safety.
Supplier: Orio Pharma
Orio Pharma, the trusted supplier of Tofacinix 11 , ensures that this essential medication is accessible to healthcare providers and patients worldwide. Their dedication to excellence in distribution guarantees timely and reliable access to Tofacinix.
Conclusion
In conclusion, Tofacinix 11 (Tofacitinib) is a groundbreaking medication for the treatment of rheumatoid arthritis and psoriatic arthritis. Manufactured by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, this targeted therapy offers a precise and effective approach to managing these chronic inflammatory conditions.
The targeted action of Tofacitinib underscores its role as a potent and well-tolerated therapeutic option. The collaboration between Beacon Pharmaceuticals Ltd and Orio Pharma ensures the highest standards of manufacturing and distribution, making Tofacinix 11 mg a reliable and accessible choice for patients seeking better health outcomes in their battle against RA and PsA.
